ClinicalTrials.gg
RecruitingNCT04393389FLOWERUpdated Aug 1, 2024

Acotec DCB Post Market Clinical Follow-up

An observational study in Peripheral Artery Disease, sponsored by Acotec Scientific Co., Ltd. Recruiting at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Acotec Scientific Co., Ltd · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.

Planned enrollment
5th of 47
3,000 · median 200
Started
2020
with 4 others
Observational
47 of 173
5 open now
Primary completion
2025-12
later than 10 of 28 live
Registered
125th of 173
by date

Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 5th largest by planned enrollment of the 47 observational ones that give a count, is one of 5 that started in 2020, is one of 47 observational ones, reaches primary completion later than 10 of the 28 other live ones, and was the 125th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Peripheral Arterial Disease with a site in Germany, or all of them as a file.
02

Study summary

All-comers, prospective, multi-center, single-arm, non-interventional post market clinical follow-up (PMCF) Cohort 1 - Claudicants: Rutherford Clinical Category (RCC) 2-3 Cohort 2 - Critical Limb Ischemia: Rutherford Clinical Category (RCC) 4-6

Read the detailed description

To prospectively collect and assess safety and efficacy data on the AcoArt drug-coated PTA balloon catheters carrying the CE Mark per current Instructions for Use in a real-world cohort of patients with symptomatic arterial disease undergoing endovascular lower limb revascularization per the institution's standard practice.

03

Conditions studied

  • Peripheral Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with symptomatic arterial disease undergoing endovascular lower limb revascularization per the institution's standard practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patient is ≥ 18 years old at the time of consent.
    1. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s) located in iliac, superficial femoral, popliteal and/or infra-popliteal arteries suitable for angioplasty per operator visual assessment.
    1. Lesion(s) can be treated with available AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") DCB device per current IFU.
    1. Subject has provided written prior to participation in the PMCF, understands the purpose of this PMCF and agrees to comply with all protocol-specified examinations and follow-up appointments.
    1. Rutherford Classification Category 2-6 Subjects with Rutherford Category 2 have gone through a conservative therapy without success.
    1. Inflow lesion treated prior to target lesion treatment

Exclusion criteria

Exclusion Criteria:

    1. Rutherford Classification Category 0, 1
    1. Patient already enrolled in other (interventional) studies that would interfere with study endpoints
    1. Inability to tolerate required antithrombotic or antiplatelet therapies.
    1. Non-dilatable severely calcified lesion.
    1. Known /allergy to components of the investigational device
    1. Un-treated acute or subacute thrombus in the target lesion.
    1. \< 1 year.
    1. Pregnancy or female patient with child bearing potential not taking adequate or currently lactating.
    1. Other comorbidities, which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up.
    1. Myocardial infarction or stroke within 30 days prior to index procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • non-CLI group

    Rutherford Clinical Category (RCC) 2-3

    Device: AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.

  • CLI group

    critical limb ischemia,Rutherford Clinical Category (RCC) 4-6

    Device: AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.

Interventions

  • DeviceAcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.

    All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint - non-CLI group

    Freedom from clinically-driven target lesion revascularization (CD-TLR) within 12 months after index procedure, which is defined as any re-intervention within the target lesion(s) due to recurrent clinical symptoms of PAD (increase of one Rutherford class or more) and/or drop of ankle-brachial index (≥20% or \>0.15 when compared with maximum early post-procedural level).

    Time frame: 12 Months

  2. Primary efficacy endpoint -CLI group

    Freedom from clinically-driven TLR within 6 months after index procedure, which is defined as any re-intervention within the target lesion(s) due to delayed or worsening wound healing, new or recurrent wound, or worsening Rutherford class.

    Time frame: 6 Months

  3. Primary safety endpoint- non-CLI group

    A composite of freedom from major adverse limb events and perioperative death (MALE-POD) through 30 days after index procedure. A major adverse limb event is defined as above-ankle amputation or major reintervention (ie, new bypass graft, major surgical graft revision such as a jump graft or an interposition graft, or thrombectomy/thrombolysis) of the treated limb.

    Time frame: 30 days

  4. Primary safety endpoint- CLI group

    A composite of freedom from device- and procedure-related mortality, freedom from major target limb amputation and TLR within 12 months post-index procedure

    Time frame: 12 Months

Secondary outcomes

  1. Rate of Any TLR (including clinically-driven and incidental TLR)

    Any TLR (including clinically-driven and incidental TLR) at 6,12, 24, 36, 48, 60 months post-procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  2. Rate of Target vessel revascularization (TVR)

    Target vessel revascularization (TVR) at 6, 12, 24, 36, 48, 60 months post-procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  3. Rate of Target limb revascularization

    Target limb revascularization at 6, 12, 24, 36, 48, 60 months post-procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  4. Rate of CD-TLR

    CD-TLR at 6, 24, 36, 48, 60 months post-procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  5. Rate of All-cause mortality

    All-cause mortality at 6, 12, 24, 36, 48, 60 months post procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60months

  6. Rate of Device- or procedure-related death

    Device- or procedure-related death at 30 days and 6 months

    Time frame: 30 days, 6 months

  7. Rate of Major amputation

    Major amputation at 6, 12, 24, 36, 48, 60 months post procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  8. Rate of Technical success

    Technical success defined as final in-lesion residual diameter stenosis ≤50% by angiographic visual estimate at the end of the index procedure without device malfunction.

    Time frame: Post procedure

  9. Rate of Procedural success

    Procedural success defined as technical success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or CD-TLR) prior to discharge

    Time frame: Post procedure

  10. Change in Rutherford clinical category (target limb)

    Changes in Rutherford clinical category (target limb) at 6, 12, 24, 36, 48, 60 months post-procedure compared to baseline

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  11. Rate of primary sustained clinical improvement

    Primary sustained clinical improvement, defined as improvement in Rutherford classification by one or more categories compared with baseline, without TLR.

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  12. Rate of secondary sustained clinical improvement

    Secondary sustained clinical improvement, defined as improvement in Rutherford classification by one or more categories compared with baseline, including patients with TLR

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  13. Rate of (Major) Amputation-free survival - CLI group

    (Major) Amputation-free survival at 6, 12, 24, 36, 48, 60 months post-procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  14. Rate of Minor amputation - CLI group

    Minor amputation at 6, 12, 24, 36, 48, 60 months post-procedure

    Time frame: 6 months,12 months,24 months, 36months,48 months,60 months

  15. Rate of Wound healing - CLI group

    healed or not; if not, improving, stagnant,worsening

    Time frame: 60 months

  16. New or recurrent wound of the target limb - CLI group

    New or recurrent wound of the target limb

    Time frame: 60 months

07

Study locations

7 of 7 sites recruiting
  • Halle
    Halle, Saxony-Anhalt, Germany
    Recruiting
    • Corneliu-Gheorge Popescu · Contact
  • Eilenburg
    Eilenburg, Germany
    Recruiting
    • Johannes Schuster · Contact
  • Department of Angiology, University Hospital Leipzig,
    Leipzig, Germany
    Recruiting
    • Andrej Schmidt · Contact
  • Elblandklinikum Radebeul
    Radebeul, Germany
    Recruiting
    • Torsten Fuss · Contact
  • Elblandklinikum Radebeul
    Riesa, Germany
    Recruiting
    • Torsten Fuss · Contact
  • REGIOMED Klinikum Sonneberg
    Sonneberg, Germany
    Recruiting
    • Marcus Thieme · Contact
  • KKH Torgau
    Torgau, Germany
    Recruiting
    • Lars Maiwald · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2025, 65 months after the start.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 65 months is above that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 19, 2020
StartActual
Jun 4, 2020
Primary completionEst.
Dec 1, 2025
CompletionEst.
Mar 1, 2027
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04393389
Lead sponsor
Acotec Scientific Co., Ltd
Responsible party
Sponsor
First posted
May 19, 2020
Start date
Jun 4, 2020
Primary completion
Dec 1, 2025 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Aug 1, 2024

Study contacts

Schmidt Andrej
Contact
Andrej.Schmidt@medizin.uni-leipzig.de
+49-341-97 ext. 18770
Schmidt Andrej
principal investigator · Department of Angiology, University Hospital Leipzig

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion